ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Maintenance of ADT or testosterone supplementation in the management of castration resistant prostate cancer
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 231127" data-attributes="member: 13851"><p><strong>Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question (2022)</strong></p><p><em>Irene Caramella ● Alberto Dalla Volta ● Marco Bergamini ● Deborah Cosentini ● Francesca Valcamonico ● Alfredo Berruti</em></p><p></p><p></p><p><strong>Abstract </strong></p><p><strong></strong></p><p><strong>Purpose</strong> <em>Whether or not the androgen receptor (AR) axis could still be targetable in castration-resistant prostate cancer (CRPC) patients with disease progression to next-generation hormonal agents (NGHAs) is a controversial issue.</em></p><p></p><p><strong>Results </strong><em>Serum testosterone in CRPC patients has a positive prognostic role and increases testosterone levels after androgen deprivation therapy (ADT) withdrawal or testosterone supplementation, as part of a bipolar androgen therapy (BAT) strategy, has been shown to potentially restore sensitivity to previous lines of NGHAs.</em></p><p></p><p><strong>Conclusion</strong><em> These data suggest that maintenance of ADT in CRPC patients receiving further lines of treatment, as recommended by current international guidelines, could be questionable. <strong>Conversely, testosterone supplementation aimed to re-sensitize CRPC to further hormonal manipulation is a strategy worth to be explored in future clinical trials.</strong></em></p><p></p><p></p><p></p><p></p><p><strong><em>In conclusion, evidence suggests that serum testosterone has a positive prognostic role in CRPC, so ADT maintenance in CRPC patients receiving concomitant AR independent therapies is questionable. Indeed, the observation of a successful rechallenge with hormonal agents after a transient restoration in testosterone levels claims the possibility to expand the efficacy of AR-targeted therapies in CRPC setting, with relevant implications for clinical practice since these agents are currently being used in the early management of a hormone-sensitive disease. <u>In order to achieve rapid testosterone recovery in CRPC patients, ADT discontinuation alone is not sufficient and hormonal replacement is required</u>.</em></strong></p><p><strong><em></em></strong></p><p><strong><em>*Testosterone can positively influence the patient's quality of life, which is a key clinical endpoint in late CRPC.</em></strong></p><p><strong><em></em></strong></p><p><strong><em>*Whether testosterone supplementation, in association with active antineoplastic therapies for patients with CRPC, should be administered continuously to achieve stable testosterone levels within normal limits or follow the BAT schedule is a matter for future research.</em></strong></p></blockquote><p></p>
[QUOTE="madman, post: 231127, member: 13851"] [B]Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question (2022)[/B] [I]Irene Caramella ● Alberto Dalla Volta ● Marco Bergamini ● Deborah Cosentini ● Francesca Valcamonico ● Alfredo Berruti[/I] [B]Abstract Purpose[/B] [I]Whether or not the androgen receptor (AR) axis could still be targetable in castration-resistant prostate cancer (CRPC) patients with disease progression to next-generation hormonal agents (NGHAs) is a controversial issue.[/I] [B]Results [/B][I]Serum testosterone in CRPC patients has a positive prognostic role and increases testosterone levels after androgen deprivation therapy (ADT) withdrawal or testosterone supplementation, as part of a bipolar androgen therapy (BAT) strategy, has been shown to potentially restore sensitivity to previous lines of NGHAs.[/I] [B]Conclusion[/B][I] These data suggest that maintenance of ADT in CRPC patients receiving further lines of treatment, as recommended by current international guidelines, could be questionable. [B]Conversely, testosterone supplementation aimed to re-sensitize CRPC to further hormonal manipulation is a strategy worth to be explored in future clinical trials.[/B][/I] [B][I]In conclusion, evidence suggests that serum testosterone has a positive prognostic role in CRPC, so ADT maintenance in CRPC patients receiving concomitant AR independent therapies is questionable. Indeed, the observation of a successful rechallenge with hormonal agents after a transient restoration in testosterone levels claims the possibility to expand the efficacy of AR-targeted therapies in CRPC setting, with relevant implications for clinical practice since these agents are currently being used in the early management of a hormone-sensitive disease. [U]In order to achieve rapid testosterone recovery in CRPC patients, ADT discontinuation alone is not sufficient and hormonal replacement is required[/U]. *Testosterone can positively influence the patient's quality of life, which is a key clinical endpoint in late CRPC. *Whether testosterone supplementation, in association with active antineoplastic therapies for patients with CRPC, should be administered continuously to achieve stable testosterone levels within normal limits or follow the BAT schedule is a matter for future research.[/I][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Maintenance of ADT or testosterone supplementation in the management of castration resistant prostate cancer
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top